Previous close | 1.6500 |
Open | 1.7500 |
Bid | 1.6900 x 1400 |
Ask | 1.7200 x 1800 |
Day's range | 1.6500 - 1.7500 |
52-week range | 0.9200 - 3.7900 |
Volume | |
Avg. volume | 4,571,537 |
Market cap | 418.603M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring the Financial and Operational Milestones of Lexicon Pharmaceuticals in the First Quarter of 2024
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).